Before a liquid hydrocarbon active pharmaceutical ingredient is charged to a tablet press, the adsorption step determines whether subsequent blending and compression can meet content uniformity limits. As-supplied 1,3-dimethyladamantane pharma grade may be supplied as a low-polarity liquid at ambient conditions; the physical form is confirmed against the vendor certificate of analysis before unit operation selection. Direct addition to a direct-compression formula can produce overwet granules, punch sticking, and unacceptable weight variation. The liquid is therefore adsorbed onto a porous carrier with oil absorption capacity measured by ISO 787-5. Carriers based on colloidal silicon dioxide or magnesium aluminometasilicate with specific surface area of 150–300 m²/g are screened. Actual loading is set below the carrier’s oil absorption saturation point, commonly at 0.7–0.9 g/g for fumed silica grades with absorption in the 200–250 g/100 g range, to retain free-flowing powder. This operation is performed in a planetary mixer or high-shear mixer with chopper speed not exceeding 1500 rpm to avoid collapsing the carrier pore structure. After adsorption, the blend is passed through an ASTM E11 30-mesh screen (600 µm) to break soft agglomerates. The resulting powder is tested for bulk density and compressibility per USP <616> and flow rate per USP <1174>. Compression uses a rotary tablet press fitted with B-tooling; precompression force is maintained at 10–20% of main compression force. Hardness values of 30–70 N and friability below 1.0% per USP <1216> are typical acceptance criteria, but values must be linked to disintegration performance because hydrophobic carrier domains can retard water ingress. Content uniformity is assessed by USP <905> with acceptance value ≤ 15.0. Tablet cores are compacted to target weight, and residual solvent limits follow ICH Q3C Class 3 solvents derived from any adsorption step; no Class 1 or Class 2 solvents should be introduced by the carrier. Dissolution performance is measured using USP <711> apparatus II at 50 rpm; if no pharmacopeial monograph exists for this API, the Q value must be justified from biobatch data. In-process sampling and testing comply with 21 CFR 211.110.

What Particle Size and Flow Attributes Govern Capsule Filling of Adsorbed 1,3-Dimethyladamantane?

Capsule filling imposes a different stress state than tableting because the powder is formed into plugs under low compression. The operating limit is not the API melting point but the bulk density and particle size distribution after adsorption. Filling trials on a tamping-pin capsule filler with pin settings between 3 mm and 8 mm are used to establish plug height. Powder blend D90 should remain below 800 µm for size 0 capsules; D10 should be above 20 µm to reduce dusting. Laser diffraction per ISO 13320:2020 or USP <429> is used. Blend flow is controlled to a Carr Index ≤ 25.0% and Hausner ratio ≤ 1.35 per USP <1174>. Adsorbed liquid API on fumed silica may exhibit thixotropic behavior; if the powder is over-dried, electrostatic charging causes adherence to capsule shells and weight variation exceeding ±5% for a 300 mg target fill weight. The capsule shell compatibility with the lipophilic liquid load is assessed by storage at 40 °C/75% RH per ICH Q1A(R2) accelerated conditions. Brittleness and cross-linking of gelatin are monitored by dissolution USP <711> with enzyme-free medium. Hydroxypropyl methylcellulose capsules may be preferred if residual moisture below 3.0% is required, but capsule shell supplier data is needed. Uniformity of dosage units follows USP <905>. If a capsule formulation is filled by weight rather than volume, in-process fill weight is checked at intervals not exceeding 30 minutes with a balance calibrated per USP <41>.

Inside a high-shear mixer, the binder fluid interacts with the adsorbed API carrier and can create a second solvation risk. The binder solution may displace the liquid API from the porous carrier if the solvent polarity is too high. Purified water alone may be unsuitable for a hydrocarbon analyte because it creates a three-phase distribution among carrier, water, and API, leading to bleed-out at granule surfaces. Granulation binders are selected from ethanol-based or isopropanol-based systems as Class 3 solvents under ICH Q3C; drying is required to residual solvent not more than 0.5% per solvent or as justified. Wet massing time is controlled by impeller amperage in a high-shear mixer with impeller tip speed of 5–10 m/s; chopper speed is maintained at 1500–3000 rpm only during the first 60–120 seconds to avoid breaking granules. Endpoint is determined by torque increase and granule size distribution by sieve analysis per ASTM E11 using 125 µm, 250 µm, 500 µm, and 850 µm sieves. Drying in a fluid-bed dryer with inlet air temperature below 60 °C is specified because higher temperature can volatilize or redistribute the liquid API depending on its vapor pressure; published data for this specific configuration is limited. Loss on drying is measured per USP <731>. Moisture content is targeted between 1.0% and 2.5% for tableting, but this must be confirmed by stability studies because hydrophobic granules can retain bound water. Milled granules are compressed after lubrication with magnesium stearate at 0.25–0.75 wt%; higher lubricant levels reduce tensile strength and retard dissolution due to the API’s lipophilic character. Tablets are evaluated by friability USP <1216> and disintegration USP <701>; disintegration times above 15 minutes trigger formulation revision.

When Dry Granulation Is Run Below the Glass Transition of the Carrier, What Process Faults Emerge?

When dry granulation of an adsorbed liquid API is performed on a roller compactor, the feed screw and roll pressure must be configured to avoid carrier attrition and liquid phase separation. If the carrier is amorphous silica, room-temperature compaction is well below its glass transition, causing brittle fracture instead of permanent deformation. Roll pressure in the range of 20–80 kN per 100 mm roll width is typical for silicate-based adsorbates; higher pressure squeezes the liquid API from the carrier pores and produces a sticky compact that blocks the mill screen. Roll gap is set at 1.5–3.0 mm. Pre-compacted ribbon density should approach 0.6–0.9 g/cm³ without reaching true density. Ribbon porosity is measured by mercury intrusion or gas pycnometry. Milling through an oscillating granulator with 0.8–1.6 mm screen produces granules; fines below 125 µm are limited to 20–30% to reduce downstream segregation. Granule size distribution is checked by USP <786> or sieve analysis. The roll-compacted granules are blended with extragranular disintegrant such as croscarmellose sodium at 2.0–5.0 wt%; this addition is split between intragranular and extragranular phases to control disintegration below 10 minutes. If the API is released from the carrier under roll pressure, it can coat the disintegrant and suppress wicking action. The formulation is therefore tested by Raman mapping or energy-dispersive X-ray spectroscopy to confirm that the API remains inside the carrier domain. Tableting of dry granulated material uses a rotary press with main compression force of 8–20 kN for 9 mm round punches. Ejection force is monitored and should remain below 350 N to avoid picking, but press setup varies by formulation. Stability protocols follow ICH Q1A(R2) long-term 25 °C/60% RH and intermediate 30 °C/65% RH conditions.

Aqueous solubility is not a reliable predictor for injectable formulation of a cage hydrocarbon API. A parenteral presentation of 1,3-dimethyladamantane requires a solubility-enabling system such as a co-solvent, cyclodextrin complex, lipid emulsion, or micellar dispersion. Pre-formulation solubility is measured by shake-flask method in water, phosphate buffer pH 7.4, and candidate vehicles before vehicle selection. Co-solvent systems containing propylene glycol or polyethylene glycol are prepared as Class 3 residual solvent-controlled formulations under ICH Q3C; final osmolality is measured by USP <785> and adjusted to 270–320 mOsm/kg for isotonicity if the product is intended for intravenous administration. Terminal sterilization is not assumed. If the formulation is heat-stable, steam sterilization at 121 °C for 15 minutes may be validated by F0 ≥ 8 minutes; otherwise aseptic filtration through a 0.22 µm filter is used.

Lyophilized vials require cryoprotectants such as mannitol or trehalose at 2–5% w/v; the cake is typically produced with primary drying at shelf temperature −25 °C to −10 °C and secondary drying at 25–35 °C, but cycle parameters are formulation-specific. Reconstituted solution must be clear or opalescent per Ph. Eur. 2.2.1 or USP <790>, with pH 3.0–8.5 unless otherwise justified. The hydrocarbon API may adsorb onto vial stoppers or tubing; extractables and leachables testing is required per USP <1663> and USP <1664> when lipophilic vehicles are present. Elemental impurities are controlled per ICH Q3D(R2); risk assessment must account for platinum or palladium residues if catalytic hydrogenation was used in API synthesis.

Granule Dispersibility Is an Independent Release Barrier in Oral Suspension Sachets

Granulated intermediates for oral suspension often reach the patient as a dry powder; dispersion in water then becomes a release barrier separate from gastric dissolution. Granules are manufactured by adsorption followed by low-shear granulation or dry granulation and are sieved to a top size of 1.0–2.0 mm. Dispersibility is evaluated by adding the sachet content to 100 mL purified water at 25 °C with stirring at 100 rpm; complete dispersion should occur within 2 minutes, but this specification must be based on intended use. Sieve retention at 250 µm after dispersion should be below 5.0% to avoid dose loss. Because the API is lipophilic, granules may float or agglomerate unless a wetting agent such as sodium lauryl sulfate at 0.1–0.5 wt% or polysorbate 80 is included. Surfactant compatibility with the lipophilic API is determined by forced degradation under ICH Q1A(R2); peroxide present in polysorbate grades can oxidize the hydrocarbon if oxidative stress is not controlled. Finished granules are tested for loss on drying USP <731>, residual solvents ICH Q3C, and microbial limits USP <1111>. If the product is a unit-dose powder in a sachet, uniformity of dosage units follows USP <905>. If the product is reconstituted into an oral suspension, deliverable volume is checked under USP <698> or equivalent pharmacopeial standard. The reconstituted suspension may require shaking to redisperse; sedimentation volume and redispersibility are evaluated by a graduated cylinder method with readings at 0.5 h, 1 h, 2 h, and 24 h to establish an in-use stability window. A lipophilic API can adhere to the dosing vessel, so rinsing and recovery studies are performed with the intended oral syringe or cup.